Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
Express News | Acumen Pharmaceuticals Inc : UBS Cuts Target Price to $6 From $14
UBS Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $6
Acument Pharmaceuticals Shares Are Trading Lower. The Stock May Be Moving on Continued Weakness After the Company Reported Worse-than-expected Q2 EPS Results Yesterday.
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
BTIG analyst Thomas Shrader maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 38.9%
H.C. Wainwright Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Andrew Fein maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 4